Literature DB >> 26091824

Deregulation of protein translation control, a potential game-changing hypothesis for Parkinson's disease pathogenesis.

Jean-Marc Taymans1, Aurore Nkiliza2, Marie-Christine Chartier-Harlin3.   

Abstract

Protein translation is one of the most fundamental and exquisitely controlled processes in biology, and is energetically demanding. The deregulation of this process is deleterious to cells, as demonstrated by several diseases caused by mutations in protein translation machinery. Emerging evidence now points to a role for protein translation in the pathogenesis of Parkinson's disease (PD); a debilitating neurodegenerative movement disorder. In this paper, we propose a hypothesis that protein translation machinery, PD-associated proteins and PD pathology are connected in a functional network linking cell survival to protein translation control. This hypothesis is a potential game changer in the field of the molecular pathogenesis of PD, with implications for the development of PD diagnostics and disease-modifying therapies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  EIF4G1; LRRK2; alpha-synuclein; ribosome; translation elongation factor; translation initiation factor

Mesh:

Year:  2015        PMID: 26091824     DOI: 10.1016/j.molmed.2015.05.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  21 in total

Review 1.  An emerging role for the ribosome as a nexus for post-translational modifications.

Authors:  Deniz Simsek; Maria Barna
Journal:  Curr Opin Cell Biol       Date:  2017-04-23       Impact factor: 8.382

2.  LRRK2 and mitochondria: Recent advances and current views.

Authors:  Alpana Singh; Lianteng Zhi; Hui Zhang
Journal:  Brain Res       Date:  2018-06-09       Impact factor: 3.252

3.  Identification of distinct blood-based biomarkers in early stage of Parkinson's disease.

Authors:  Yingyan Wu; Qian Yao; Guo-Xin Jiang; Gang Wang; Qi Cheng
Journal:  Neurol Sci       Date:  2019-12-11       Impact factor: 3.307

4.  Parkinson's disease: From human genetics to clinical trials.

Authors:  Marcel P van der Brug; Andrew Singleton; Thomas Gasser; Patrick A Lewis
Journal:  Sci Transl Med       Date:  2015-09-16       Impact factor: 17.956

Review 5.  Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.

Authors:  Liesel Goveas; Eugénie Mutez; Marie-Christine Chartier-Harlin; Jean-Marc Taymans
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

6.  Mitochondrial dysfunction induces dendritic loss via eIF2α phosphorylation.

Authors:  Taiichi Tsuyama; Asako Tsubouchi; Tadao Usui; Hiromi Imamura; Tadashi Uemura
Journal:  J Cell Biol       Date:  2017-02-16       Impact factor: 10.539

7.  ATXN2 a culprit with multiple facets.

Authors:  Aurore Nkiliza; Marie-Christine Chartier-Harlin
Journal:  Oncotarget       Date:  2017-05-23

Review 8.  Dissecting the role of Engrailed in adult dopaminergic neurons--Insights into Parkinson disease pathogenesis.

Authors:  Hocine Rekaik; François-Xavier Blaudin de Thé; Alain Prochiantz; Julia Fuchs; Rajiv L Joshi
Journal:  FEBS Lett       Date:  2015-10-13       Impact factor: 4.124

9.  Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases.

Authors:  Martin Steger; Francesca Tonelli; Genta Ito; Paul Davies; Matthias Trost; Melanie Vetter; Stefanie Wachter; Esben Lorentzen; Graham Duddy; Stephen Wilson; Marco As Baptista; Brian K Fiske; Matthew J Fell; John A Morrow; Alastair D Reith; Dario R Alessi; Matthias Mann
Journal:  Elife       Date:  2016-01-29       Impact factor: 8.140

10.  PINK1 expression increases during brain development and stem cell differentiation, and affects the development of GFAP-positive astrocytes.

Authors:  Insup Choi; Dong-Joo Choi; Haijie Yang; Joo Hong Woo; Mi-Yoon Chang; Joo Yeon Kim; Woong Sun; Sang-Myun Park; Ilo Jou; Sang-Hun Lee; Sang Hoon Lee; Eun-Hye Joe
Journal:  Mol Brain       Date:  2016-01-08       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.